PMID- 20392899
OWN - NLM
STAT- MEDLINE
DCOM- 20100806
LR  - 20200205
IS  - 1465-2099 (Electronic)
IS  - 0022-1317 (Linking)
VI  - 91
IP  - Pt 8
DP  - 2010 Aug
TI  - Patient HLA-DRB1* and -DQB1* allele and haplotype association with hepatitis C 
      virus persistence and clearance.
PG  - 1931-1938
LID - 10.1099/vir.0.018119-0 [doi]
AB  - Hepatitis C virus (HCV) infection is prevalent throughout the world and 
      interferon (IFN)-based treatments are currently the only therapeutic option. 
      However, depending upon variations in their human leukocyte antigen (HLA), some 
      patients do not respond well to IFN therapy. The current study evaluated the HLA 
      allele and haplotype distribution of 204 HCV-seropositive individuals from 
      Islamabad, Pakistan, who were receiving standard IFN therapy. In this cohort, 150 
      patients (74%) showed a sustained virological response to IFN therapy, whereas 54 
      (26%) did not. In addition to the HCV patients, 102 unrelated healthy volunteers 
      were used as controls. DNA was isolated from the blood of the patients and 
      controls for HLA-DRB1 and HLA-DQB1 allele typing, whilst plasma was used for HCV 
      detection and genotyping. HLA-DRB1*04 was found to impart a significant 
      protective advantage [Bonferroni-corrected P value (pc)=0.047] against HCV 
      infection. In patients on IFN therapy, HLA-DRB1*11 and -DQB1*0301 (pc=0.044) were 
      found to be associated with viral clearance. In contrast, HLA-DRB1*07 (pc=0.008) 
      individually or in combination with HLA-DQB1*02 was found to be associated with 
      viral persistence. These associations of HLA with HCV persistence or clearance 
      will be beneficial in deciding the therapeutic regimen for Pakistani patients 
      infected with HCV genotype 3a.
FAU - Ali, Lubna
AU  - Ali L
AD  - Institute of Biomedical and Genetic Engineering (IBGE), PO Box No. 2891, 
      Islamabad 44000, Pakistan.
FAU - Mansoor, Atika
AU  - Mansoor A
AD  - Institute of Biomedical and Genetic Engineering (IBGE), PO Box No. 2891, 
      Islamabad 44000, Pakistan.
FAU - Ahmad, Nafees
AU  - Ahmad N
AD  - Institute of Developmental Genetics, HelmHoltz Zentrum Munchen, Neuherberg, 
      Germany.
AD  - Institute of Biomedical and Genetic Engineering (IBGE), PO Box No. 2891, 
      Islamabad 44000, Pakistan.
FAU - Siddiqi, Saima
AU  - Siddiqi S
AD  - Institute of Biomedical and Genetic Engineering (IBGE), PO Box No. 2891, 
      Islamabad 44000, Pakistan.
FAU - Mazhar, Kehkashan
AU  - Mazhar K
AD  - Institute of Biomedical and Genetic Engineering (IBGE), PO Box No. 2891, 
      Islamabad 44000, Pakistan.
FAU - Muazzam, Ambreen G
AU  - Muazzam AG
AD  - Institute of Biomedical and Genetic Engineering (IBGE), PO Box No. 2891, 
      Islamabad 44000, Pakistan.
FAU - Qamar, Raheel
AU  - Qamar R
AD  - Shifa College of Medicine, Pitras Bokhari Road H-8/4, Islamabad 44000, Pakistan.
AD  - COMSATS Institute of Information Technology, Park Road, Chak Shahzad, Islamabad 
      44000, Pakistan.
FAU - Khan, Khalid M
AU  - Khan KM
AD  - Pir Mehr Ali Shah Arid Agriculture University, Rawalpindi 46000, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100414
PL  - England
TA  - J Gen Virol
JT  - The Journal of general virology
JID - 0077340
RN  - 0 (Antiviral Agents)
RN  - 0 (HLA-DQ Antigens)
RN  - 0 (HLA-DQ beta-Chains)
RN  - 0 (HLA-DQB1 antigen)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (HLA-DRB1 Chains)
RN  - 9008-11-1 (Interferons)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Alleles
MH  - Antiviral Agents/immunology/therapeutic use
MH  - Female
MH  - HLA-DQ Antigens/*genetics
MH  - HLA-DQ beta-Chains
MH  - HLA-DR Antigens/*genetics
MH  - HLA-DRB1 Chains
MH  - Haplotypes
MH  - Hepacivirus/*immunology
MH  - Hepatitis C/*drug therapy/*immunology
MH  - Humans
MH  - Interferons/*immunology/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Pakistan
MH  - Young Adult
EDAT- 2010/04/16 06:00
MHDA- 2010/08/07 06:00
CRDT- 2010/04/16 06:00
PHST- 2010/04/16 06:00 [entrez]
PHST- 2010/04/16 06:00 [pubmed]
PHST- 2010/08/07 06:00 [medline]
AID - 10.1099/vir.0.018119-0 [doi]
PST - ppublish
SO  - J Gen Virol. 2010 Aug;91(Pt 8):1931-1938. doi: 10.1099/vir.0.018119-0. Epub 2010 
      Apr 14.